The U.S. Food and Drug Administration is deepening its own use of artificial intelligence. Less than a year after launching its internal AI tool, Elsa, the agency released Elsa 4.0 and connected it to a new unified data platform that pulls together roughly 40 previously separate systems, so staff can query agency data directly instead of uploading documents each time. New features include custom AI agents, document generation, data analysis and visualization, and better search. FDA says humans stay involved at every step and that the model is not trained on data submitted by regulated companies.
On the same day, the then-Commissioner announced a pilot of “one-day inspections” for facilities that AI-driven risk analysis flags as lower risk. These are short screening visits meant to supplement, not replace, full inspections. More than 40 have been completed since April 2026, mostly ending with no action indicated classifications, though inspectors can still issue formal observations and can expand the visit on the spot. Companies are not told in advance whether they are in the pilot, so life sciences startups with manufacturing or clinical sites should stay ready for either format. Complex or higher-risk operations, such as sterile manufacturing, remain on the standard inspection track.
